March 22, 2000: Lorus Therapeutics Announces New Management Appointments
TORONTO--(BUSINESS WIRE)--March 22, 2000--Philippe G. Lacaille, chair and chief executive officer of Lorus Therapeutics Inc. (OTCBB:LORFF - news; TSE:LOR. - news; ``Lorus') is pleased to announce the appointment of Geoffrey S. Collett as vice-president of corporate development and James T. Parsons, CA as vice-president of finance and administration and chief financial officer of Lorus.
``The appointments of corporate executives such as Geoffrey Collett and James Parsons to Lorus fortifies our management team and contributes toward our objective of accelerating the growth and success of Lorus,' said Philippe G. Lacaille, chair and chief executive officer of Lorus Therapeutics Inc. ``By strengthening our team of experts on both the scientific and business sides, Lorus is solidifying its position as a leading anti-cancer biotechnology company.'
As vice-president, corporate development, Mr. Collett will be responsible for the implementation of a corporate partnering strategy and will lead other corporate growth initiatives in the areas of business development and mergers and acquisitions.
Mr. Collett brings to this position over 15 years of multi-national pharmaceutical management experience gained at Boehringer Ingelheim, Inc. and Glaxo Wellcome Inc. Most recently, Mr. Collett was vice-president of MDS Capital Corp. with responsibility for venture capital investing in biotechnology companies.
As chief financial officer of Lorus, Mr. Parsons will be responsible for achieving Lorus' financial objectives and will work in tandem with Mr. Collett on mergers and acquisitions.
Mr. Parsons brings over 10 years of financial and management experience in financings, acquisitions, treasury and business controls. Formerly with the audit firm KPMG, Mr. Parsons worked for two research-driven Canadian public companies. Most recently, Mr. Parsons was the controller and assistant treasurer of Timminco Limited, a specialty metals company servicing pharmaceutical and other industries.
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the OTC BB exchange under the symbol LORFF. |
